In fact, it was recently shown that aberrantly expressed CD90 and CD133 are strongly associated with reduced sensitivity to anticancer therapy, and contribute to disease progression and poor survival rates (overall survival and disease-free survival) in patients with hepatoblastoma [32], which is consistent with the demonstrated therapeutic success of targeting the CD90/β3 integrin/AMPK/CD133 signaling axis in liver cancer reported by Chen WC et al. [20], and concordant with current knowledge of the pluripotent/stemness-defining role of CD133 and CD90 in HCC [25]. Here, THY1 is linked to liver cancer.